Current management of toxoplasmosis relies on conventional therapy, which has important shortcomings related to reduced tolerance and overall potency, poor efficacy to the latent stage of the parasite, as well as drug resistance . Prevailing treatments are based on combination therapies comprising sulfonamides and pyrimethamine . Additional treatments against acute toxoplasmosis include combinations with other agents that interfere in folate synthesis such as dapsone, but also protein synthesis inhibitors (e.g., clindamycin, azithromycin, clarithromycin, erythromycin, spiramycin), and inhibitors of apicoplast division such as doxycycline and minocycline . Toxoplasmosis poses an unmet and challenging medication need, and novel options are required .